Monthly Archives: March 2015

Gour Medical SA, a veterinary biomedical company founded by Israeli entrepreneur Serge Goldner, has entered into a definitive worldwide license agreement with Actelion Pharmaceuticals Ltd for the veterinary development of one of Actelion’s early-stage clinical dual orexin receptor antagonists, which the company had decided not to pursue further. Gour plans...

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), is about to start a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML). The Phase 2b study will examine its ability to improve outcomes for AML patients who have achieved remission after standard treatment by eliminating the...

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PSTI) has shown strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation. In the study, conducted in conjunction with Hadassah Medical Center’s Department of Bone Marrow Transplantation and Cancer Immunotherapy, mice with damaged bone marrow who...

Israeli-American biotech Chiasma has raised $70 million as it moves toward FDA approval with a treatment for the hormone disorder acromegaly. With the money, Chiasma plans to file an FDA application for oral octreotide, a treatment for the rare disorder. The company expects to submit the drug next quarter and,...